Aquinox Pharmaceuticals Inc. (AQXP) Earns Outperform Rating from Analysts at Leerink Swann
Analysts at Leerink Swann initiated coverage on shares of Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) in a report issued on Tuesday. The firm set an “outperform” rating and a $24.00 price target on the stock. Leerink Swann’s price target points to a potential upside of 76.99% from the stock’s previous close.
Several other brokerages have also recently commented on AQXP. Jefferies Group boosted their price objective on shares of Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the company a “hold” rating in a research note on Friday, August 5th. Canaccord Genuity set a $22.00 price objective on shares of Aquinox Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, July 21st. Finally, Zacks Investment Research cut shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 9th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Aquinox Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $20.00.
Aquinox Pharmaceuticals (NASDAQ:AQXP) remained flat at $13.56 during trading on Tuesday. 199,851 shares of the company’s stock traded hands. Aquinox Pharmaceuticals has a one year low of $6.01 and a one year high of $16.75. The company has a 50 day moving average of $12.45 and a 200-day moving average of $9.17. The firm’s market capitalization is $233.39 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/09/aquinox-pharmaceuticals-inc-aqxp-earns-outperform-rating-from-analysts-at-leerink-swann.html
Aquinox Pharmaceuticals (NASDAQ:AQXP) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.22. On average, equities analysts forecast that Aquinox Pharmaceuticals will post ($2.23) earnings per share for the current fiscal year.
In related news, major shareholder Bros. Advisors Lp Baker purchased 2,783,605 shares of the business’s stock in a transaction on Tuesday, September 20th. The stock was acquired at an average price of $12.25 per share, with a total value of $34,099,161.25. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 3.00% of the stock is currently owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in AQXP. Franklin Resources Inc. raised its stake in shares of Aquinox Pharmaceuticals by 7.6% in the first quarter. Franklin Resources Inc. now owns 1,245,945 shares of the company’s stock worth $10,989,000 after buying an additional 87,600 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Aquinox Pharmaceuticals by 5,277.2% in the first quarter. Goldman Sachs Group Inc. now owns 970,317 shares of the company’s stock worth $8,558,000 after buying an additional 952,272 shares during the last quarter. BlackRock Inc. raised its stake in shares of Aquinox Pharmaceuticals by 24.3% in the first quarter. BlackRock Inc. now owns 50,600 shares of the company’s stock worth $446,000 after buying an additional 9,900 shares during the last quarter. Royce & Associates LP raised its stake in shares of Aquinox Pharmaceuticals by 416.4% in the first quarter. Royce & Associates LP now owns 96,167 shares of the company’s stock worth $848,000 after buying an additional 77,545 shares during the last quarter. Finally, BlackRock Group LTD raised its stake in shares of Aquinox Pharmaceuticals by 23.4% in the first quarter. BlackRock Group LTD now owns 200,100 shares of the company’s stock worth $1,765,000 after buying an additional 37,900 shares during the last quarter. 68.20% of the stock is owned by institutional investors and hedge funds.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.